An open ‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine
This study compared the serotonin transporter (SERT) occupancy achieved by SEP‐227162 and ODV, at daily doses of 25, 50, 100, and 150 mg using [11C]DASB positron emission tomography (PET). Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25, 50, 100, and150 mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was performed after 72 hr at each dose l...
Source: Synapse - December 13, 2017 Category: Neurology Authors: W. Gordon Frankle, Brigitte Robertson, Gary Maier, Jennifer Paris, Deanna Asmonga, Maureen May, Michael L. Himes, N. Scott Mason, Chester A. Mathis, Rajesh Narendran Tags: RESEARCH ARTICLE Source Type: research
Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations
Clinical Pharmacology in Drug Development,Volume 7, Issue 4, Page 441-450, May 2018. (Source: Clinical Pharmacology in Drug Development)
Source: Clinical Pharmacology in Drug Development - December 11, 2017 Category: Drugs & Pharmacology Authors: Alice I.Nichols
,
SamLiao
,
RichatAbbas Source Type: research
An Open ‐Label Positron Emission Tomography (PET) Study to Evaluate Serotonin Transporter Occupancy Following Escalating Dosing Regimens of (R)‐(‐)‐O‐desmethylvenlafaxine and Racemic O‐Desmethylvenlafaxine
Conclusion: In vitro data suggests a ratio of 3.3:1 for binding at human SERT for SEP‐227162 relative to ODV. Our study suggests a ratio of 1.7:1, highlighting the value of in vivo imaging in the drug development process. This article is protected by copyright. All rights reserved.
It has been shown that minimally effective doses of SSRIs (including paroxetine, sertraline, citalopram, fluoxetine, venlafaxine) responsible for antidepressant activity clinically correspond to steady‐state serotonin transporter (SERT) occupancies of ∼80%. This study examined the SERT occupancy of SEP‐227162, an enantiomer of desvenlaf...
Source: Synapse - December 8, 2017 Category: Neurology Authors: W. Gordon Frankle, Brigitte Robertson, Gary Maier, Jennifer Paris, Deanna Asmonga, Maureen May, Michael L Himes, N. Scott Mason, Chester A. Mathis, Rajesh Narendran Tags: Research Article Source Type: research
Risk of hair loss with different antidepressants: a comparative retrospective cohort study
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion, wit...
Source: International Clinical Psychopharmacology - December 1, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - November 30, 2017 Category: Pediatrics Authors: Karen L. Weihs William Murphy Richat Abbas Deborah Chiles Richard D. England Sara Ramaker Dalia B. Wajsbrot Source Type: research
Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder
Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - November 29, 2017 Category: Pediatrics Authors: Sarah Atkinson Shannon Lubaczewski Sara Ramaker Richard D. England Dalia B. Wajsbrot Richat Abbas Robert L. Findling Source Type: research
Takotsubo Cardiomyopathy and Intraoperative Cardiac Arrest: Is Desvenlafaxine a Contributing Factor?
Takotsubo cardiomyopathy (TTC), otherwise known as stress-induced cardiomyopathy (broken heart syndrome) is characterized by rapidly reversible heart failure with transient left ventricular wall motion abnormality without the presence of significant coronary artery disease.1 According to a review, perioperative TTC occurs in 1 of 6,700 surgical procedures.2 (Source: Journal of Cardiothoracic and Vascular Anesthesia)
Source: Journal of Cardiothoracic and Vascular Anesthesia - November 16, 2017 Category: Anesthesiology Authors: Usha Gurunathan Tags: Letter to the Editor Source Type: research
Categorical improvement in functional impairment in depressed patients treated with desvenlafaxine.
CONCLUSIONS: Treatment with desvenlafaxine 50 or 100 mg/d led to significantly greater categorical improvement in functional impairment versus placebo, and improvement in SDS subscale scores significantly predicted functional outcome. Monitoring patient progress early in the course of antidepressant treatment using a functional assessment such as the SDS may help clinicians determine whether or not treatment adjustments are needed.
PMID: 29140227 [PubMed - as supplied by publisher] (Source: CNS Spectrums)
Source: CNS Spectrums - November 15, 2017 Category: Neurology Authors: Soares CN, Zhang M, Boucher M Tags: CNS Spectr Source Type: research
Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome.
CONCLUSION: MB is a useful additional strategy for severe drug induced vasodilatory shock and may be potentially life-saving. Clinicians should be aware that it can interact with other drugs and cause life-threatening Serotonin Syndrome. Lower doses or shorter durations may be wise in patients at risk of this interaction.
PMID: 29134498 [PubMed - as supplied by publisher] (Source: Journal of Medical Toxicology)
Source: Journal of Medical Toxicology - November 13, 2017 Category: Toxicology Authors: Chan BS, Becker T, Chiew AL, Abdalla AM, Robertson TA, Liu X, Roberts MS, Buckley NA Tags: J Med Toxicol Source Type: research
Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations
Abstract
Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single‐ and multiple‐dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a population PK model previously developed using sparse PK samples from patients with major depressive disorder, including 140 Korean patients, combined with rich PK data from healthy volunteers. The structural PK model was an open 1‐compartment linear disposition model with parallel first‐order and 0‐order inputs. The effects of Korean status on apparent oral cleara...
Source: Clinical Pharmacology in Drug Development - November 1, 2017 Category: Drugs & Pharmacology Authors: Alice I. Nichols, Sam Liao, Richat Abbas Tags: Original Manuscript Source Type: research
Antidepressant-related jitteriness syndrome in anxiety and depressive disorders: Incidence and risk factors.
This study examined the incidence and pattern of antidepressant-related JS and its predictors.
METHODS: 209 patients diagnosed with any anxiety or depressive disorder and started on mirtazapine, sertraline, desvenlafaxine, escitalopram or fluoxetine were assessed at baseline, after 2 weeks, and after 6 weeks with psychopathology rating scales and for predefined categories of JS.
RESULTS: The incidence of JS during the 6-week study was 27.7%, but only 6.7% in first 2 weeks. JS rates were similar in anxiety and depressive disorders. Mirtazapine was associated with the lowest rate of 14.3%, and other antidepre...
Source: Asian Journal of Psychiatry - October 26, 2017 Category: Psychiatry Tags: Asian J Psychiatr Source Type: research
The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine
We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50–100 mg/day for 8 weeks. Multiple regression analyses modeled improvement in work functioning measures (Lam Employment Absence and Productivity Scale, Health and Work Performance Questionnaire, Sheehan Disability Scale) with measures of fatigue (Patient-Reported Outcomes Measurement Information Syste...
Source: International Clinical Psychopharmacology - September 28, 2017 Category: Psychiatry Tags: Original Articles Source Type: research
Prediction of human efficacious antidepressant doses using the mouse forced swim test
Publication date: Available online 6 September 2017 Source:Pharmacology Biochemistry and Behavior Author(s): Eunice Yuen, Steven Swanson, Jeffrey M. Witkin The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experime...
Source: Pharmacology Biochemistry and Behavior - September 7, 2017 Category: Biochemistry Source Type: research
Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use
AbstractOral desvenlafaxine extended-release [Deller® (Brazil); Pristiq® (USA)] is a second-generation, selective serotonin-noradrenalin reuptake inhibitor that is indicated for the treatment of major depressive disorder (MDD) in adults. In this population, desvenlafaxine is an effective and generally well tolerated treatment, significantly improving symptoms of depression and functional outcomes compared with placebo in 8-week double-blind trials, with these benefits maintained during longer-term therapy. In addition, desvenlafaxine is an effective and generally well tolerated treatment in postmenopausal women with vaso...
Source: Drugs and Therapy Perspectives - September 2, 2017 Category: Drugs & Pharmacology Source Type: research
A standardization of the Novelty-Suppressed Feeding Test protocol in rats
Publication date: 29 September 2017 Source:Neuroscience Letters, Volume 658 Author(s): Arantxa Blasco-Serra, Eva M. González-Soler, Ana Cervera-Ferri, Vicent Teruel-Martí, Alfonso A. Valverde-Navarro Tests based on hyponeophagia phenomena are the most widely used to check the efficacy and efficiency of new-generation chronic antidepressant treatments. Even so, these tests lack strict consensus about their methodology, which reduces their validity, reproducibility and makes translatability difficult. Therefore, after an extensive literature review on this subject, we propose a methodological protocol for the Novelt...
Source: Neuroscience Letters - September 1, 2017 Category: Neuroscience Source Type: research
